|
1
|
Pirillo A, Casula M, Olmastroni E, Norata
GD and Catapano AL: Global epidemiology of dyslipidaemias. Nat Rev
Cardiol. 18:689–700. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Repositioning of the global epicentre of
non-optimal cholesterol. Nature. 582:73–77. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu T, Zhao D and Qi Y: Global trends in
the epidemiology and management of dyslipidemia. J Clin Med.
11:63772022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou XD, Targher G, Byrne CD, Somers V,
Kim SU, Chahal CAA, Wong VW, Cai J, Shapiro MD, Eslam M, et al: An
international multidisciplinary consensus statement on MAFLD and
the risk of CVD. Hepatol Int. 17:773–791. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang L, Li Z, Song Y, Liu Y, Zhao H, Liu
Y, Zhang T, Yuan Y, Cai X, Wang S, et al: Study on urine metabolic
profiling and pathogenesis of hyperlipidemia. Clin Chim Acta.
495:365–373. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corvilain B: Lipoprotein metabolism. Rev
Med Brux. 18:3–9. 1997.(In French). PubMed/NCBI
|
|
7
|
Errico TL, Chen X, Martin Campos JM, Julve
J, Escolà-Gil JC and Blanco-Vaca F: Basic mechanisms: Structure,
function and metabolism of plasma lipoproteins. Clin Investig
Arterioscler. 25:98–103. 2013.PubMed/NCBI
|
|
8
|
Mach F, Baigent C, Catapano AL, Koskinas
KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V,
Ference BA, et al: 2019 ESC/EAS Guidelines for the management of
dyslipidaemias: Lipid modification to reduce cardiovascular risk.
Eur Heart J. 41:111–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chapman MJ, Ginsberg HN, Amarenco P,
Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen
PT, Kuivenhoven JA, et al: Triglyceride-rich lipoproteins and
High-density lipoprotein cholesterol in patients at high risk of
cardiovascular disease: Evidence and guidance for management. Eur
Heart J. 32:1345–1361. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chait A, Ginsberg HN, Vaisar T, Heinecke
JW, Goldberg IJ and Bornfeldt KE: Remnants of the triglyceride-rich
lipoproteins, diabetes, and cardiovascular disease. Diabetes.
69:508–516. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vallejo-Vaz AJ, Fayyad R, Boekholdt SM,
Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD and Ray
KK: Triglyceride-rich lipoprotein cholesterol and risk of
cardiovascular events among patients receiving statin therapy in
the TNT trial. Circulation. 138:770–781. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Raposeiras-Roubin S, Rosselló X, Oliva B,
Fernández-Friera L, Mendiguren JM, Andrés V, Bueno H, Sanz J,
Martínez de Vega V, Abu-Assi E, et al: Triglycerides and residual
atherosclerotic risk. J Am Coll Cardiol. 77:3031–3041. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borén J, Chapman MJ, Krauss RM, Packard
CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls
SJ, et al: Low-density lipoproteins cause atherosclerotic
cardiovascular disease: Pathophysiological, genetic, and
therapeutic insights: A consensus statement from the European
Atherosclerosis Society Consensus Panel. Eur Heart J. 41:2313–2330.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gotto AM Jr and Brinton EA: Assessing low
levels of High-density lipoprotein cholesterol as a risk factor in
coronary heart disease: A working group report and update. J Am
Coll Cardiol. 43:717–724. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li JJ, Ma CS, Zhao D and Yan XW:
Lipoprotein(a) and cardiovascular disease in Chinese population: A
beijing heart society expert scientific statement. JACC Asia.
2:653–665. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehta A, Vasquez N, Ayers CR, Patel J,
Hooda A, Khera A, Blumenthal RS, Shapiro MD, Rodriguez CJ, Tsai MY,
et al: Independent association of lipoprotein(a) and coronary
artery calcification with atherosclerotic cardiovascular risk. J Am
Coll Cardiol. 79:757–768. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ong KL, McClelland RL, Allison MA, Cushman
M, Garg PK, Tsai MY, Rye KA and Tabet F: Lipoprotein (a) and
coronary artery calcification: Prospective study assessing
interactions with other risk factors. Metabolism. 116:1547062021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Roth GA, Mensah GA, Johnson CO, Addolorato
G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ,
Benziger CP, et al: Global burden of cardiovascular diseases and
risk factors, 1990–2019: Update from the GBD 2019 study. J Am Coll
Cardiol. 76:2982–3021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Unwin N and Alberti KG: Chronic
non-communicable diseases. Annals of tropical medicine and
parasitology. 100:455–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lyu Y, Jiang X and Dai W: The roles of a
novel inflammatory neopterin in subjects with coronary
atherosclerotic heart disease. Int Immunopharmacol. 24:169–172.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Libby P, Ridker PM and Hansson GK:
Progress and challenges in translating the biology of
atherosclerosis. Nature. 473:317–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
NCD Risk Factor Collaboration (NCD-RisC),
. Repositioning of the global epicentre of Non-optimal cholesterol.
Nature. 582:73–77. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song PK, Man QQ, Li H, Pang SJ, Jia SS, Li
YQ, He L, Zhao WH and Zhang J: Trends in lipids level and
dyslipidemia among chinese adults, 2002–2015. Biomed Environ Sci.
32:559–570. 2019.PubMed/NCBI
|
|
24
|
Pan L, Yang Z, Wu Y, Yin RX, Liao Y, Wang
J, Gao B and Zhang L; China National Survey of Chronic Kidney
Disease Working Group, : The prevalence, awareness, treatment and
control of dyslipidemia among adults in China. Atherosclerosis.
248:2–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li JJ: Chinese guideline for lipid
management (2023): A new guideline rich in domestic elements for
controlling dyslipidemia. J Geriatr Cardiol. 20:618–620. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xia Q, Chen Y, Yu Z, Huang Z, Yang Y, Mao
A and Qiu W: Prevalence, awareness, treatment, and control of
dyslipidemia in Chinese adults: A systematic review and
meta-analysis. Front Cardiovasc Med. 10:11863302023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S, Liu HH, Guo YL, Zhu CG, Wu NQ, Xu
RX, Dong Q and Li JJ: Improvement of evaluation in Chinese patients
with atherosclerotic cardiovascular disease using the
Very-high-risk refinement: A population-based study. Lancet Reg
Health West Pac. 17:1002862021.PubMed/NCBI
|
|
28
|
Rygiel K: Hypertriglyceridemia-common
causes, prevention and treatment strategies. Curr Cardiol Rev.
14:67–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mc Namara K, Alzubaidi H and Jackson JK:
Cardiovascular disease as a leading cause of death: How are
pharmacists getting involved? Integr Pharm Res Pract. 8:1–11.
2019.PubMed/NCBI
|
|
30
|
Vaezi Z and Amini A: Familial
Hypercholesterolemia. StatPearls. StatPearls Publishing Copyright ©
2025, StatPearls Publishing LLC; Treasure Island (FL): ineligible
companies. Disclosure: Afshin Amini declares no relevant financial
relationships with ineligible companies. 2025
|
|
31
|
Benn M, Watts GF, Tybjaerg-Hansen A and
Nordestgaard BG: Mutations causative of familial
hypercholesterolaemia: Screening of 98 098 individuals from the
Copenhagen General Population Study estimated a prevalence of 1 in
217. Eur Heart J. 37:1384–1394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nordestgaard BG, Chapman MJ, Humphries SE,
Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ,
Defesche JC, et al: Familial hypercholesterolaemia is
underdiagnosed and undertreated in the general population: Guidance
for clinicians to prevent coronary heart disease: Consensus
statement of the European atherosclerosis society. Eur Heart J.
34:3478–3490a. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vrablik M, Tichy L, Freiberger T, Blaha V,
Satny M and Hubacek JA: Genetics of familial hypercholesterolemia:
New insights. Front Genet. 11:5744742020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun D, Zhou BY, Li S, Sun NL, Hua Q, Wu
SL, Cao YS, Guo YL, Wu NQ, Zhu CG, et al: Genetic basis of index
patients with familial hypercholesterolemia in Chinese population:
Mutation spectrum and Genotype-phenotype correlation. Lipids Health
Dis. 17:2522018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Benito-Vicente A, Uribe KB, Jebari S,
Galicia-Garcia U, Ostolaza H and Martin C: Familial
Hypercholesterolemia: The most frequent cholesterol metabolism
disorder caused disease. Int J Mol Sci. 19:34262018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sawhney JPS and Madan K: Familial
hypercholesterolemia. Indian Heart J. 76 (Suppl 1):S108–S112. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hopkins PN, Toth PP, Ballantyne CM and
Rader DJ; National Lipid Association Expert Panel on Familial
Hypercholesterolemia, : Familial hypercholesterolemias: Prevalence,
genetics, diagnosis and screening recommendations from the National
Lipid Association Expert Panel on Familial Hypercholesterolemia. J
Clin Lipidol. 5 (3 Suppl):S9–S17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Singh S and Bittner V: Familial
hypercholesterolemia-epidemiology, diagnosis, and screening. Curr
Atheroscler Rep. 17:4822015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi D, Malick WA, Koenig W, Rader DJ and
Rosenson RS: Familial Hypercholesterolemia: Challenges for a
High-Risk Population: JACC Focus Seminar 1/3. J Am Coll Cardiol.
81:1621–1632. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garg A and Radhakrishnan S: Pediatric
hyperlipidemia. Indian Heart J. 76 (Suppl 1):S104–S107. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hegele RA, Boren J, Ginsberg HN, Arca M,
Averna M, Binder CJ, Calabresi L, Chapman MJ, Cuchel M, von
Eckardstein A, et al: Rare dyslipidaemias, from phenotype to
genotype to management: A European Atherosclerosis Society task
force consensus statement. Lancet Diabetes Endocrinol. 8:50–67.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cao YX, Sun D, Liu HH, Jin JL, Li S, Guo
YL, Wu NQ, Zhu CG, Liu G, Dong Q, et al: Improvement of definite
diagnosis of familial hypercholesterolemia using an expanding
genetic analysis. JACC Asia. 1:82–89. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gill PK and Hegele RA: Familial combined
hyperlipidemia is a polygenic trait. Curr Opin Lipidol. 33:126–132.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nawawi HM, Chua YA and Watts GF: The brave
new world of genetic testing in the management of the
dyslipidaemias. Curr Opin Cardiol. 35:226–233. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Taghizadeh E, Farahani N, Mardani R,
Taheri F, Taghizadeh H and Gheibihayat SM: Genetics of familial
combined hyperlipidemia (FCHL) disorder: An update. Biochem Genet.
60:453–481. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Trinder M, Vikulova D, Pimstone S, Mancini
GBJ and Brunham LR: Polygenic architecture and cardiovascular risk
of familial combined hyperlipidemia. Atherosclerosis. 340:35–43.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wierzbicki AS, Kim EJ, Esan O and
Ramachandran R: Hypertriglyceridaemia: An update. J Clin Pathol.
75:798–806. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Arner P, Bernard S, Salehpour M, Possnert
G, Liebl J, Steier P, Buchholz BA, Eriksson M, Arner E, Hauner H,
et al: Dynamics of human adipose lipid turnover in health and
metabolic disease. Nature. 478:110–113. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Horswell SD, Fryer LG, Hutchison CE,
Zindrou D, Speedy HE, Town MM, Duncan EJ, Sivapackianathan R, Patel
HN, Jones EL, et al: CDKN2B expression in adipose tissue of
familial combined hyperlipidemia patients. J Lipid Res.
54:3491–3505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Naukkarinen J, Ehnholm C and Peltonen L:
Genetics of familial combined hyperlipidemia. Curr Opin Lipidol.
17:285–290. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Heidemann BE, Koopal C, Baass A, Defesche
JC, Zuurbier L, Mulder MT, Roeters van Lennep JE, Riksen NP, Boot
C, Marais AD and Visseren FLJ: Establishing the relationship
between familial dysbetalipoproteinemia and genetic variants in the
APOE gene. Clin Genet. 102:253–261. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Koopal C, Marais AD and Visseren FL:
Familial dysbetalipoproteinemia: An underdiagnosed lipid disorder.
Curr Opin Endocrinol Diabetes Obes. 24:133–139. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Krauss RM, Lu JT, Higgins JJ, Clary CM and
Tabibiazar R: VLDL receptor gene therapy for reducing atherogenic
lipoproteins. Mol Metab. 69:1016852023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Packard CJ and Shepherd J: Lipoprotein
heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb
Vasc Biol. 17:3542–3556. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rasmussen KL, Tybjaerg-Hansen A,
Nordestgaard BG and Frikke-Schmidt R: Plasma levels of
apolipoprotein E, APOE genotype, and All-cause and cause-specific
mortality in 105 949 individuals from a white general population
cohort. Eur Heart J. 40:2813–2824. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bennet AM, Di Angelantonio E, Ye Z,
Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de
Faire U and Danesh J: Association of apolipoprotein E genotypes
with lipid levels and coronary risk. JAMA. 298:1300–1311. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Khan TA, Shah T, Prieto D, Zhang W, Price
J, Fowkes GR, Cooper J, Talmud PJ, Humphries SE, Sundstrom J, et
al: Apolipoprotein E genotype, cardiovascular biomarkers and risk
of stroke: Systematic review and meta-analysis of 14,015 stroke
cases and pooled analysis of primary biomarker data from up to
60,883 individuals. Int J Epidemiol. 42:475–492. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Koopal C, Geerlings MI, Muller M, de Borst
GJ, Algra A, van der Graaf Y and Visseren FL; SMART Study Group, :
The relation between apolipoprotein E (APOE) genotype and
peripheral artery disease in patients at high risk for
cardiovascular disease. Atherosclerosis. 246:187–192. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mahley RW, Weisgraber KH and Huang Y:
Apolipoprotein E4: A causative factor and therapeutic target in
neuropathology, including Alzheimer's disease. Proc Natl Acad Sci
USA. 103:5644–5651. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Goldberg RB and Chait A: A comprehensive
update on the chylomicronemia syndrome. Front Endocrinol
(Lausanne). 11:5939312020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Hegele RA, Berberich AJ, Ban MR, Wang J,
Digenio A, Alexander VJ, D'Erasmo L, Arca M, Jones A, Bruckert E,
et al: Clinical and biochemical features of different molecular
etiologies of familial chylomicronemia. J Clin Lipidol.
12:920–927.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Paquette M, Bernard S, Hegele RA and Baass
A: Chylomicronemia: Differences between familial chylomicronemia
syndrome and multifactorial chylomicronemia. Atherosclerosis.
283:137–142. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Koseki M, Yamashita S, Ogura M, Ishigaki
Y, Ono K, Tsukamoto K, Hori M, Matsuki K, Yokoyama S and
Harada-Shiba M: Current diagnosis and management of tangier
disease. J Atheroscler Thromb. 28:802–810. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Vitali C, Bajaj A, Nguyen C, Schnall J,
Chen J, Stylianou K, Rader DJ and Cuchel M: A systematic review of
the natural history and biomarkers of primary lecithin: Cholesterol
acyltransferase deficiency. J Lipid Res. 63:1001692022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Mensink RP, Zock PL, Kester AD and Katan
MB: Effects of dietary fatty acids and carbohydrates on the ratio
of serum total to HDL cholesterol and on serum lipids and
apolipoproteins: A Meta-analysis of 60 controlled trials. Am J Clin
Nutr. 77:1146–1155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Authors/Task Force Members; ESC Committee
for Practice Guidelines (CPG); ESC National Cardiac Societies, :
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid
modification to reduce cardiovascular risk. Atherosclerosis.
290:140–205. 2019. View Article : Google Scholar
|
|
67
|
Trautwein EA and McKay S: The role of
specific components of a Plant-based diet in management of
dyslipidemia and the impact on cardiovascular risk. Nutrients.
12:26712020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gengatharan JM, Handzlik MK, Chih ZY,
Ruchhoeft ML, Secrest P, Ashley EL, Green CR, Wallace M, Gordts
PLSM and Metallo CM: Altered sphingolipid biosynthetic flux and
lipoprotein trafficking contribute to trans-fat-induced
atherosclerosis. Cell Metab. 37:274–290.e9. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hieronimus B and Stanhope KL: Dietary
fructose and dyslipidemia: New mechanisms involving apolipoprotein
CIII. Curr Opin Lipidol. 31:20–26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yan H, Niimi M, Matsuhisa F, Zhou H,
Kitajima S, Chen Y, Wang C, Yang X, Yao J, Yang D, et al:
Apolipoprotein CIII deficiency protects against atherosclerosis in
knockout rabbits. Arterioscler Thromb Vasc Biol. 40:2095–2107.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Rohr MW, Narasimhulu CA, Rudeski-Rohr TA
and Parthasarathy S: Negative effects of a High-Fat diet on
intestinal permeability: A review. Adv Nutr. 11:77–91. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Dimitriadis G, Mitrou P, Lambadiari V,
Maratou E and Raptis SA: Insulin effects in muscle and adipose
tissue. Diabetes Res Clin Pract. 93 (Suppl 1):S52–S59. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Su X, Cheng Y, Zhang G and Wang B: Novel
insights into the pathological mechanisms of metabolic related
dyslipidemia. Mol Biol Rep. 48:5675–5687. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen SC and Tseng CH: Dyslipidemia, kidney
disease, and cardiovascular disease in diabetic patients. Rev
Diabet Stud. 10:88–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fukui T and Hirano T: High-density
lipoprotein subspecies between patients with type 1 diabetes and
type 2 diabetes without/with intensive insulin therapy. Endocr J.
59:561–569. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hirano T: Pathophysiology of diabetic
dyslipidemia. J Atheroscler Thromb. 25:771–782. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cao X, Liu XM and Zhou LH: Recent progress
in research on the distribution and function of NUCB2/nesfatin-1 in
peripheral tissues. Endocr J. 60:1021–1027. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Basar O, Akbal E, Köklü S, Koçak E, Tuna
Y, Ekiz F, Gültuna S, Yιlmaz FM and Aydoğan T: A novel appetite
peptide, nesfatin-1 in patients with non-alcoholic fatty liver
disease. Scand J Clin Lab Invest. 72:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yin Y, Li Z, Gao L, Li Y, Zhao J and Zhang
W: AMPK-dependent modulation of hepatic lipid metabolism by
nesfatin-1. Mol Cell Endocrinol. 417:20–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nasri A, Kowaluk M, Widenmaier SB and
Unniappan S: Nesfatin-1 and nesfatin-1-like peptide attenuate
hepatocyte lipid accumulation and nucleobindin-1 disruption
modulates lipid metabolic pathways. Commun Biol. 7:6232024.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ajoolabady A, Pratico D, Mazidi M, Davies
IG, Lip GYH, Seidah N, Libby P, Kroemer G and Ren J: PCSK9 in
metabolism and diseases. Metabolism. 163:1560642024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Rosso C, Kazankov K, Younes R, Esmaili S,
Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, et
al: Crosstalk between adipose tissue insulin resistance and liver
macrophages in Non-alcoholic fatty liver disease. J Hepatol.
71:1012–1021. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Verges B, Petit JM, Duvillard L, Dautin G,
Florentin E, Galland F and Gambert P: Adiponectin is an important
determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol.
26:1364–1369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Biondi B: Thyroid and obesity: An
intriguing relationship. J Clin Endocrinol Metab. 95:3614–3617.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Obregon MJ: Thyroid hormone and adipocyte
differentiation. Thyroid. 18:185–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Grover GJ, Mellstrom K and Malm J:
Therapeutic potential for thyroid hormone receptor-beta selective
agonists for treating obesity, hyperlipidemia and diabetes. Curr
Vasc Pharmacol. 5:141–154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lu C and Cheng SY: Thyroid hormone
receptors regulate adipogenesis and carcinogenesis via crosstalk
signaling with peroxisome proliferator-activated receptors. J Mol
Endocrinol. 44:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Su X, Peng H, Chen X, Wu X and Wang B:
Hyperlipidemia and hypothyroidism. Clin Chim Acta. 527:61–70. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pearce EN: Update in lipid alterations in
subclinical hypothyroidism. J Clin Endocrinol Metab. 97:326–333.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chi X, Britt EC, Shows HW, Hjelmaas AJ,
Shetty SK, Cushing EM, Li W, Dou A, Zhang R and Davies BSJ: ANGPTL8
promotes the ability of ANGPTL3 to bind and inhibit lipoprotein
lipase. Mol Metab. 6:1137–1149. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Moradi H and Vaziri ND: Molecular
mechanisms of disorders of lipid metabolism in chronic kidney
disease. Front Biosci (Landmark Ed). 23:146–161. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Borba EF, Bonfá E, Vinagre CG, Ramires JA
and Maranhão RC: Chylomicron metabolism is markedly altered in
systemic lupus erythematosus. Arthritis Rheum. 43:1033–1040. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
de Carvalho JF, Bonfá E and Borba EF:
Systemic lupus erythematosus and ‘lupus dyslipoproteinemia’.
Autoimmun Rev. 7:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
McMahon M, Grossman J, Skaggs B,
Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson
K, Wong WK, Volkmann E, et al: Dysfunctional proinflammatory
High-density lipoproteins confer increased risk of atherosclerosis
in women with systemic lupus erythematosus. Arthritis Rheum.
60:2428–2437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Tselios K, Koumaras C, Gladman DD and
Urowitz MB: Dyslipidemia in systemic lupus erythematosus: Just
another comorbidity? Semin Arthritis Rheum. 45:604–610. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cox AJ, West NP and Cripps AW: Obesity,
inflammation, and the gut microbiota. Lancet Diabetes Endocrinol.
3:207–215. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fei N and Zhao L: An opportunistic
pathogen isolated from the gut of an obese human causes obesity in
germfree mice. ISME J. 7:880–884. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jia X, Xu W, Zhang L, Li X, Wang R and Wu
S: Impact of gut microbiota and Microbiota-related metabolites on
hyperlipidemia. Front Cell Infect Microbiol. 11:6347802021.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Blaak EE, Canfora EE, Theis S, Frost G,
Groen AK, Mithieux G, Nauta A, Scott K, Stahl B, van Harsselaar J,
et al: Short chain fatty acids in human gut and metabolic health.
Benef Microbes. 11:411–455. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chambers ES, Byrne CS, Morrison DJ, Murphy
KG, Preston T, Tedford C, Garcia-Perez I, Fountana S,
Serrano-Contreras JI, Holmes E, et al: Dietary supplementation with
inulin-propionate ester or inulin improves insulin sensitivity in
adults with overweight and obesity with distinct effects on the gut
microbiota, plasma metabolome and systemic inflammatory responses:
A randomised cross-over trial. Gut. 68:1430–1438. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Byrne CS, Chambers ES, Preston T, Tedford
C, Brignardello J, Garcia-Perez I, Holmes E, Wallis GA, Morrison DJ
and Frost GS: Effects of inulin propionate ester incorporated into
palatable food products on appetite and resting energy expenditure:
A randomised crossover study. Nutrients. 11:8612019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
van Deuren T, Blaak EE and Canfora EE:
Butyrate to combat obesity and Obesity-associated metabolic
disorders: Current status and future implications for therapeutic
use. Obes Rev. 23:e134982022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Chambers ES, Viardot A, Psichas A,
Morrison DJ, Murphy KG, Zac-Varghese SE, MacDougall K, Preston T,
Tedford C, Finlayson GS, et al: Effects of targeted delivery of
propionate to the human colon on appetite regulation, body weight
maintenance and adiposity in overweight adults. Gut. 64:1744–1754.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tu J, Wang Y, Jin L and Huang W: Bile
acids, gut microbiota and metabolic surgery. Front Endocrinol
(Lausanne). 13:9295302022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J,
Chen W, Hylemon PB and Zhou H: Bile acid receptors and the
Gut-liver axis in nonalcoholic fatty liver disease. Cells.
10:28062021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Clifford BL, Sedgeman LR, Williams KJ,
Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC,
Wahlström A, Ashby JW, et al: FXR activation protects against NAFLD
via bile-acid-dependent reductions in lipid absorption. Cell Metab.
33:1671–1684.e4. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Gao K, Mu CL, Farzi A and Zhu WY:
Tryptophan metabolism: A link between the gut microbiota and brain.
Adv Nutr. 11:709–723. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Natividad JM, Agus A, Planchais J, Lamas
B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R,
Straube M, et al: Impaired aryl hydrocarbon receptor ligand
production by the gut microbiota is a key factor in metabolic
syndrome. Cell Metab. 28:737–749.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Postal BG, Ghezzal S, Aguanno D, André S,
Garbin K, Genser L, Brot-Laroche E, Poitou C, Soula H, Leturque A,
et al: AhR activation defends gut barrier integrity against damage
occurring in obesity. Mol Metab. 39:1010072020. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zelante T, Iannitti RG, Cunha C, De Luca
A, Giovannini G, Pieraccini G, Zecchi R, D'Angelo C,
Massi-Benedetti C, Fallarino F, et al: Tryptophan catabolites from
microbiota engage aryl hydrocarbon receptor and balance mucosal
reactivity via interleukin-22. Immunity. 39:372–385. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang Y, Ai Z, Xing X, Fan Y, Zhang Y, Nan
B, Li X, Wang Y and Liu J: The ameliorative effect of probiotics on
diet-induced lipid metabolism disorders: A review. Crit Rev Food
Sci Nutr. 64:3556–3572. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Liang C, Zhou XH, Gong PM, Niu HY, Lyu LZ,
Wu YF, Han X and Zhang LW: Lactiplantibacillus plantarum H-87
prevents high-fat diet-induced obesity by regulating bile acid
metabolism in C57BL/6J mice. Food Funct. 12:4315–4324. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Oh N, Lee J, Kim H, Kwon M, Seo J and Roh
S: Comparison of Cell-free extracts from three newly identified
lactobacillus plantarum strains on the inhibitory effect of
adipogenic differentiation and insulin resistance in 3T3-L1
adipocytes. Biomed Res Int. 2021:66765022021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Rahman MS, Kang I, Lee Y, Habib MA, Choi
BJ, Kang JS, Park DS and Kim YS: Bifidobacterium longum subsp.
infantis YB0411 Inhibits Adipogenesis in 3T3-L1 Pre-adipocytes and
reduces High-Fat-Diet-induced obesity in mice. J Agric Food Chem.
69:6032–6042. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
In Kim H, Kim JK, Kim JY, Jang SE, Han MJ
and Kim DH: Lactobacillus plantarum LC27 and Bifidobacterium longum
LC67 simultaneously alleviate high-fat diet-induced colitis,
endotoxemia, liver steatosis, and obesity in mice. Nutr Res.
67:78–89. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Xu W, Yu J, Yang Y, Li Z, Zhang Y, Zhang
F, Wang Q, Xie Y, Zhao B and Wu C: Strain-level screening of human
gut microbes identifies Blautia producta as a new
anti-hyperlipidemic probiotic. Gut Microbes. 15:22280452023.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lorkowski S: Long known and mostly unused:
Lifestyle measures to support Lipid-lowering therapy. Dtsch Med
Wochenschr. 147:796–806. 2022.(In German). PubMed/NCBI
|
|
118
|
National Clinical Guideline Centre (UK), .
National Institute for Health and Clinical Excellence: Guidance:
Lipid Modification: Cardiovascular Risk Assessment and the
Modification of Blood Lipids for the Primary and Secondary
Prevention of Cardiovascular Disease. National Institute for Health
and Care Excellence (UK), 2014. Copyright © National Clinical
Guideline Centre; London: 2014
|
|
119
|
Hirota T, Fujita Y and Ieiri I: An updated
review of pharmacokinetic drug interactions and phar macogenetics
of statins. Expert Opin Drug Metab Toxicol. 16:809–822. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Watts GF, Barrett PH, Ji J, Serone AP,
Chan DC, Croft KD, Loehrer F and Johnson AG: Differential
regulation of lipoprotein kinetics by atorvastatin and fenofibrate
in subjects with the metabolic syndrome. Diabetes. 52:803–811.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhang X, Xing L, Jia X, Pang X, Xiang Q,
Zhao X, Ma L, Liu Z, Hu K, Wang Z and Cui Y: Comparative
Lipid-Lowering/Increasing Efficacy of 7 statins in patients with
dyslipidemia, cardiovascular diseases, or diabetes mellitus:
Systematic review and network Meta-analyses of 50 randomized
controlled trials. Cardiovasc Ther. 2020:39870652020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Cannon CP, Steinberg BA, Murphy SA, Mega
JL and Braunwald E: Meta-analysis of cardiovascular outcomes trials
comparing intensive versus moderate statin therapy. J Am Coll
Cardiol. 48:438–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Cholesterol Treatment Trialists' (CTT)
Collaboration, . Baigent C, Blackwell L, Emberson J, Holland LE,
Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al: Efficacy and
safety of more intensive lowering of LDL cholesterol: A
meta-analysis of data from 170,000 participants in 26 randomised
trials. Lancet. 376:1670–1681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cholesterol Treatment Trialists' (CTT)
Collaboration, . Baigent C, Blackwell L, Emberson J, Holland LE,
Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al: Efficacy and
safety of LDL-lowering therapy among men and women: Meta-analysis
of individual data from 174,000 participants in 27 randomised
trials. Lancet. 385:1397–1405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ridker PM, Danielson E, Fonseca FA, Genest
J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ,
MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men
and women with elevated C-reactive protein. N Engl J Med.
359:2195–2207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Rodriguez F, Maron DJ, Knowles JW, Virani
SS, Lin S and Heidenreich PA: Association between intensity of
statin therapy and mortality in patients with atherosclerotic
cardiovascular disease. JAMA Cardiol. 2:47–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Turner RM and Pirmohamed M: Statin-related
myotoxicity: A comprehensive review of pharmacokinetic,
pharmacogenomic and muscle components. J Clin Med. 9:222019.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Zhang H, Plutzky J, Skentzos S, Morrison
F, Mar P, Shubina M and Turchin A: Discontinuation of statins in
routine care settings: A cohort study. Ann Intern Med. 158:526–534.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Feingold KR: Maximizing the benefits of
cholesterol-lowering drugs. Curr Opin Lipidol. 30:388–394. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Berberich AJ and Hegele RA: A Modern
approach to dyslipidemia. Endocr Rev. 43:611–653. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Cannon CP, Blazing MA, Giugliano RP,
McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO,
Jukema JW, et al: Ezetimibe added to statin therapy after acute
coronary syndromes. N Engl J Med. 372:2387–2397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Sharp Collaborative Group, : Study of
heart and renal protection (SHARP): Randomized trial to assess the
effects of lowering Low-density lipoprotein cholesterol among 9,438
patients with chronic kidney disease. Am Heart J. 160:785–794.e10.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Chen J, Lou H, Jiang B, Shao R, Ruan Z and
Wang J: Simultaneous determination of hyzetimibe and its main
active metabolite in plasma by LC-MS/MS and its application in PK
study. Bioanalysis. 7:1857–1867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chen W, Ruan Z, Chen J, Yang D, Shao R,
Lou H and Jiang B: Population pharmacokinetics and enterohepatic
recirculation of hyzetimibe and its main metabolite in Chinese
healthy subjects. Br J Clin Pharmacol. 88:3153–3161. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Liao J, Wang X, Li Z and Ouyang D:
Pharmacokinetic study of Oral 14C-radiolabeled hyzetimibe, a new
cholesterol absorption inhibitor. Front Pharmacol. 12:6653722021.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ruan Z, Jiang B, Chen J, Zhang X, Lou H,
Xiang M, Shao Q and Wang J: Pharmacokinetics, pharmacodynamics,
safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese
subjects. J Clin Pharmacol. 54:1144–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Knapp HH, Schrott H, Ma P, Knopp R, Chin
B, Gaziano JM, Donovan JM, Burke SK and Davidson MH: Efficacy and
safety of combination simvastatin and colesevelam in patients with
primary hypercholesterolemia. Am J Med. 110:352–360. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Mazidi M, Rezaie P, Karimi E and Kengne
AP: The effects of bile acid sequestrants on lipid profile and
blood glucose concentrations: A systematic review and meta-analysis
of randomized controlled trials. Int J Cardiol. 227:850–857. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Crouse JR III: Hypertriglyceridemia: A
contraindication to the use of bile acid binding resins. Am J Med.
83:243–248. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Guo S, Xia XD, Gu HM and Zhang DW:
Proprotein convertase Subtilisin/Kexin-type 9 and lipid Metabolism.
Adv Exp Med Biol. 1276:137–156. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Rakipovski G, Hovingh GK and Nyberg M:
Proprotein convertase Subtilisin/Kexin type 9 inhibition as the
next statin? Curr Opin Lipidol. 31:340–346. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Lee S and Cannon CP: Combination
Lipid-lowering therapies for the prevention of recurrent
cardiovascular events. Curr Cardiol Rep. 20:552018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Nicholls SJ, Puri R, Anderson T,
Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun
H, Yang J, et al: Effect of evolocumab on progression of coronary
disease in Statin-treated patients: The GLAGOV randomized clinical
trial. JAMA. 316:2373–2384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Chen Y, Yuan Z, Lu J, Eliaschewitz FG,
Lorenzatti AJ, Monsalvo ML, Wang N, Hamer AW and Ge J: Randomized
study of evolocumab in patients with type 2 diabetes and
dyslipidaemia on background statin: Pre-specified analysis of the
Chinese population from the BERSON clinical trial. Diabetes Obes
Metab. 21:1464–1473. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
O'Donoghue ML, Giugliano RP, Wiviott SD,
Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH,
López JAG, et al: Long-term evolocumab in patients with established
atherosclerotic cardiovascular disease. Circulation. 146:1109–1119.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Han Y, Chen J, Chopra VK, Zhang S, Su G,
Ma C, Huang Z, Ma Y, Yao Z, Yuan Z, et al: ODYSSEY EAST: Alirocumab
efficacy and safety vs ezetimibe in high cardiovascular risk
patients with hypercholesterolemia and on maximally tolerated
statin in China, India, and Thailand. J Clin Lipidol. 14:98–108.
e1082020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Cao YX, Liu HH, Li S and Li JJ: A
Meta-analysis of the effect of PCSK9-monoclonal antibodies on
circulating lipoprotein (a) levels. Am J Cardiovasc Drugs.
19:87–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Robinson JG, Farnier M, Krempf M, Bergeron
J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M,
et al: Efficacy and safety of alirocumab in reducing lipids and
cardiovascular events. N Engl J Med. 372:1489–1499. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Stein EA and Turner TA: Are the PCSK9
inhibitors the panacea of atherosclerosis treatment? Expert Rev
Cardiovasc Ther. 15:491–494. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Thedrez A, Blom DJ, Ramin-Mangata S,
Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B,
Bourane S, et al: Homozygous familial hypercholesterolemia patients
with identical mutations variably express the LDLR (Low-Density
Lipoprotein Receptor): Implications for the efficacy of evolocumab.
Arterioscler Thromb Vasc Biol. 38:592–598. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Keam SJ: Tafolecimab: First Approval.
Drugs. 83:1545–1549. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Chai M, He Y, Zhao W, Han X, Zhao G, Ma X,
Qiao P, Shi D, Liu Y, Han W, et al: Efficacy and safety of
tafolecimab in Chinese patients with heterozygous familial
hypercholesterolemia: A randomized, double-blind,
placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 21:772023.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Qi L, Liu D, Qu Y, Chen B, Meng H, Zhu L,
Li L, Wang S, Liu C, Zheng G, et al: Tafolecimab in Chinese
patients with hypercholesterolemia (CREDIT-4): A randomized,
Double-Blind, Placebo-controlled phase 3 trial. JACC Asia.
3:636–645. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Huo Y, Chen B, Lian Q, Wang S, Liu L, Lu
D, Qu Y, Zheng G, Li L, Ji Y, et al: Tafolecimab in Chinese
patients with non-familial hypercholesterolemia (CREDIT-1): A
48-week randomized, double-blind, placebo-controlled phase 3 trial.
Lancet Reg Health West Pac. 41:1009072023.PubMed/NCBI
|
|
155
|
Brandts J and Ray KK: Small interfering
RNA to proprotein convertase subtilisin/kexin type 9: Transforming
LDL-cholesterol-lowering strategies. Curr Opin Lipidol. 31:182–186.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Fitzgerald K, White S, Borodovsky A,
Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel
J, Brooks A, et al: A highly durable RNAi therapeutic inhibitor of
PCSK9. N Engl J Med. 376:41–51. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Raal FJ, Kallend D, Ray KK, Turner T,
Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA,
et al: Inclisiran for the treatment of heterozygous familial
hypercholesterolemia. N Engl J Med. 382:1520–1530. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Ray KK, Wright RS, Kallend D, Koenig W,
Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ,
et al: Two phase 3 trials of inclisiran in patients with elevated
LDL cholesterol. N Engl J Med. 382:1507–1519. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Khan SA, Naz A, Qamar Masood M and Shah R:
Meta-Analysis of inclisiran for the treatment of
hypercholesterolemia. Am J Cardiol. 134:69–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wright RS, Raal FJ, Koenig W, Landmesser
U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang
X, et al: Inclisiran administration potently and durably lowers
LDL-C over an extended-term follow-up: The ORION-8 trial.
Cardiovasc Res. 120:1400–1410. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Tawara K, Tomikawa M and Abiko Y: Mode of
action of probucol in reducing serum cholesterol in mice. Jpn J
Pharmacol. 40:123–133. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Yamashita S, Masuda D and Matsuzawa Y: Did
we abandon probucol too soon? Curr Opin Lipidol. 26:304–316. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Burke AC, Telford DE and Huff MW:
Bempedoic acid: Effects on lipoprotein metabolism and
atherosclerosis. Curr Opin Lipidol. 30:1–9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Ballantyne CM, Laufs U, Ray KK, Leiter LA,
Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X and Catapano
AL: Bempedoic acid plus ezetimibe fixed-dose combination in
patients with hypercholesterolemia and high CVD risk treated with
maximally tolerated statin therapy. Eur J Prev Cardiol. 27:593–603.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
De Filippo O, D'Ascenzo F, Iannaccone M,
Bertaina M, Leone A, Borzillo I, Ravetti E, Solano A, Pagliassotto
I, Nebiolo M, et al: Safety and efficacy of bempedoic acid: A
systematic review and Meta-analysis of randomised controlled
trials. Cardiovasc Diabetol. 22:3242023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Hamayal M, Shahid W, Akhtar CH, Shekiba F,
Iftikhar I, Tahir MD, Awwab M, Hussain S, Naeem S and Hafeez M:
Risk of cardiovascular outcomes with bempedoic acid in High-risk
statin intolerant patients: A systematic review and meta analysis.
Future Cardiol. 20:639–650. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Xue H, Zhang M, Liu J, Wang J and Ren G:
Structure-based mechanism and inhibition of cholesteryl ester
transfer protein. Curr Atheroscler Rep. 25:155–166. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Doggrell SA: What have we learnt from the
clinical outcomes trials with the cetrapibs? Curr Opin Lipidol.
29:327–332. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Tardif JC, Dube MP, Pfeffer MA, Waters DD,
Koenig W, Maggioni AP, McMurray JJV, Mooser V, White HD, Heinonen
T, et al: Study design of Dal-GenE, a pharmacogenetic trial
targeting reduction of cardiovascular events with dalcetrapib. Am
Heart J. 222:157–165. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Tardif JC, Pfeffer MA, Kouz S, Koenig W,
Maggioni AP, McMurray JJV, Mooser V, Waters DD, Grégoire JC,
L'Allier PL, et al: Pharmacogenetics-guided dalcetrapib therapy
after an acute coronary syndrome: The dal-GenE trial. Eur Heart J.
43:3947–3956. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Ballantyne CM, Ditmarsch M, Kastelein JJ,
Nelson AJ, Kling D, Hsieh A, Curcio DL, Maki KC, Davidson MH and
Nicholls SJ: Obicetrapib plus ezetimibe as an adjunct to
high-intensity statin therapy: A randomized phase 2 trial. J Clin
Lipidol. 17:491–503. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Raal FJ, Santos RD, Blom DJ, Marais AD,
Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber
S, et al: Mipomersen, an apolipoprotein B synthesis inhibitor, for
lowering of LDL cholesterol concentrations in patients with
homozygous familial hypercholesterolaemia: A randomised,
double-blind, placebo-controlled trial. Lancet. 375:998–1006. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Fogacci F, Ferri N, Toth PP, Ruscica M,
Corsini A and Cicero AFG: Efficacy and safety of mipomersen: A
systematic review and Meta-analysis of randomized clinical trials.
Drugs. 79:751–766. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Reeskamp LF, Kastelein JJP, Moriarty PM,
Duell PB, Catapano AL, Santos RD and Ballantyne CM: Safety and
efficacy of mipomersen in patients with heterozygous familial
hypercholesterolemia. Atherosclerosis. 280:109–117. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Santos RD, Duell PB, East C, Guyton JR,
Moriarty PM, Chin W and Mittleman RS: Long-term efficacy and safety
of mipomersen in patients with familial hypercholesterolaemia:
2-year interim results of an open-label extension. Eur Heart J.
36:566–575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Hashemi N, Odze RD, McGowan MP, Santos RD,
Stroes ESG and Cohen DE: Liver histology during Mipomersen therapy
for severe hypercholesterolemia. J Clin Lipidol. 8:606–611. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Nurmohamed NS, Navar AM and Kastelein JJP:
New and emerging therapies for reduction of LDL-cholesterol and
apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol.
77:1564–1575. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Brunham LR and Hegele RA: Lomitapide for
the treatment of homozygous familial hypercholesterolaemia in
children. Lancet Diabetes Endocrinol. 12:866–867. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Cuchel M, Meagher EA, du Toit Theron H,
Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK,
Gaudet D, et al: Efficacy and safety of a microsomal triglyceride
transfer protein inhibitor in patients with homozygous familial
hypercholesterolaemia: A single-arm, open-label, phase 3 study.
Lancet. 381:40–46. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Blom DJ, Averna MR, Meagher EA, du Toit
Theron H, Sirtori CR, Hegele RA, Shah PK, Gaudet D, Stefanutti C,
Vigna GB, et al: Long-Term efficacy and safety of the microsomal
triglyceride transfer protein inhibitor lomitapide in patients with
homozygous familial hypercholesterolemia. Circulation. 136:332–335.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Nohara A, Otsubo Y, Yanagi K, Yoshida M,
Ikewaki K, Harada-Shiba M and Jurecka A: Safety and efficacy of
lomitapide in japanese patients with homozygous familial
hypercholesterolemia (HoFH): Results from the AEGR-733-301
Long-term extension study. J Atheroscler Thromb. 26:368–377. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Jun M, Foote C, Lv J, Neal B, Patel A,
Nicholls SJ, Grobbee DE, Cass A, Chalmers J and Perkovic V: Effects
of fibrates on cardiovascular outcomes: A systematic review and
meta-analysis. Lancet. 375:1875–1884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Keech A, Simes RJ, Barter P, Best J, Scott
R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al:
Effects of Long-term fenofibrate therapy on cardiovascular events
in 9795 people with type 2 diabetes mellitus (the FIELD study):
Randomised controlled trial. Lancet. 366:1849–1861. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Rubins HB, Robins SJ, Collins D, Fye CL,
Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G,
et al: Gemfibrozil for the secondary prevention of coronary heart
disease in men with low levels of high-density lipoprotein
cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol
Intervention Trial Study Group. N Engl J Med. 341:410–418. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Fruchart JC, Hermans MP, Fruchart-Najib J
and Kodama T: Selective peroxisome Proliferator-activated receptor
alpha modulators (SPPARMα) in the metabolic syndrome: Is
Pemafibrate light at the end of the tunnel? Curr Atheroscler Rep.
23:32021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Diabetes Canada Clinical Practice
Guidelines Expert Committee, . Mancini GBJ, Hegele RA and Leiter
LA: Dyslipidemia. Can J Diabetes. 42 (Suppl 1):S178–S185. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Blair HA: Pemafibrate: First Global
Approval. Drugs. 77:1805–1810. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Fruchart JC, Hermans MP and Fruchart-Najib
J: Selective peroxisome proliferator-Activated receptor alpha
modulators (SPPARMalpha): New opportunities to reduce residual
cardiovascular risk in chronic kidney disease? Curr Atheroscler
Rep. 22:432020. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Yokote K, Yamashita S, Arai H, Araki E,
Suganami H and Ishibashi S; On Behalf Of The K-Study Group, :
Long-term efficacy and safety of pemafibrate, a novel selective
peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα),
in dyslipidemic patients with renal impairment. Int J Mol Sci.
20:7062019. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Tuteja S: Activation of HCAR2 by niacin:
Benefits beyond lipid lowering. Pharmacogenomics. 20:1143–1150.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
HPS2-THRIVE Collaborative Group, . Landray
MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus
K, Craig M, Jiang L, et al: Effects of extended-release niacin with
laropiprant in high-risk patients. N Engl J Med. 371:203–212. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Lavigne PM and Karas RH: The current state
of niacin in cardiovascular disease prevention: A systematic review
and Meta-regression. J Am Coll Cardiol. 61:440–446. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Liu QK: Triglyceride-lowering and
anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids
for atherosclerotic cardiovascular risk reduction. J Clin Lipidol.
15:556–568. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Bhatt DL, Steg PG, Miller M, Brinton EA,
Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz
C, et al: Cardiovascular Risk Reduction with Icosapent Ethyl for
Hypertriglyceridemia. N Engl J Med. 380:11–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Khan SU, Lone AN, Khan MS, Virani SS,
Blumenthal RS, Nasir K, Miller M, Michos ED, Ballantyne CM, Boden
WE and Bhatt DL: Effect of omega-3 fatty acids on cardiovascular
outcomes: A systematic review and meta-analysis. EClinicalMedicine.
38:1009972021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Nishizaki Y, Miyauchi K, Iwata H, Inoue T,
Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y,
et al: Study protocol and baseline characteristics of Randomized
trial for Evaluation in Secondary Prevention Efficacy of
Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA,
the combination of a randomized control trial and an observational
biomarker study. Am Heart J. 257:1–8. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Ng DS: Evolving ANGPTL-based
lipid-lowering strategies and beyond. Curr Opin Lipidol.
32:271–272. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Dewey FE, Gusarova V, Dunbar RL,
O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV,
Bruse S, Dansky HM, et al: Genetic and pharmacologic inactivation
of ANGPTL3 and cardiovascular disease. N Engl J Med. 377:211–221.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh
GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, et
al: Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl
J Med. 383:711–720. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Wiegman A, Greber-Platzer S, Ali S,
Reijman MD, Brinton EA, Charng MJ, Srinivasan S, Baker-Smith C,
Baum S, Brothers JA, et al: Evinacumab for pediatric patients with
homozygous familial hypercholesterolemia. Circulation. 149:343–353.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Gaudet D, Greber-Platzer S, Reeskamp LF,
Iannuzzo G, Rosenson RS, Saheb S, Stefanutti C, Stroes E, Wiegman
A, Turner T, et al: Evinacumab in homozygous familial
hypercholesterolaemia: Long-term safety and efficacy. Eur Heart J.
45:2422–2434. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Rosenson RS, Gaudet D, Ballantyne CM, Baum
SJ, Bergeron J, Kershaw EE, Moriarty PM, Rubba P, Whitcomb DC,
Banerjee P, et al: Evinacumab in severe hypertriglyceridemia with
or without lipoprotein lipase pathway mutations: A phase 2
randomized trial. Nat Med. 29:729–737. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Gouni-Berthold I, Schwarz J and Berthold
HK: Updates in drug treatment of severe hypertriglyceridemia. Curr
Atheroscler Rep. 25:701–709. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Bergmark BA, Marston NA, Bramson CR, Curto
M, Ramos V, Jevne A, Kuder JF, Park JG, Murphy SA, Verma S, et al:
Effect of Vupanorsen on Non-high-density lipoprotein cholesterol
levels in statin-treated patients with elevated cholesterol:
TRANSLATE-TIMI 70. Circulation. 145:1377–1386. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Zimerman A, Wiviott SD, Park JG, Murphy
SA, Ran X, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, et al:
Hepatic fat changes with antisense oligonucleotide therapy
targeting ANGPTL3. J Clin Lipidol. 18:e261–e268. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu
W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, et al: Cardiovascular
and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl
J Med. 377:222–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Minicocci I, Montali A, Robciuc MR,
Quagliarini F, Censi V, Labbadia G, Gabiati C, Pigna G, Sepe ML,
Pannozzo F, et al: Mutations in the ANGPTL3 gene and familial
combined hypolipidemia: A clinical and biochemical
characterization. J Clin Endocrinol Metab. 97:E1266–E1275. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Watts GF, Schwabe C, Scott R, Gladding PA,
Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, et
al: RNA interference targeting ANGPTL3 for triglyceride and
cholesterol lowering: Phase 1 basket trial cohorts. Nat Med.
29:2216–2223. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Rosenson RS, Gaudet D, Hegele RA,
Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin
M, Chang T, et al: Zodasiran, an RNAi Therapeutic Targeting
ANGPTL3, for Mixed hyperlipidemia. N Engl J Med. 391:913–925. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Peloso GM, Auer PL, Bis JC, Voorman A,
Morrison AC, Stitziel NO, Brody JA, Khetarpal SA, Crosby JR,
Fornage M, et al: Association of low-frequency and rare
coding-sequence variants with blood lipids and coronary heart
disease in 56,000 whites and blacks. Am J Hum Genet. 94:223–232.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Chen YQ, Pottanat TG, Siegel RW, Ehsani M,
Qian YW, Zhen EY, Regmi A, Roell WC, Guo H, Luo MJ, et al:
Angiopoietin-like protein 8 differentially regulates ANGPTL3 and
ANGPTL4 during postprandial partitioning of fatty acids. J Lipid
Res. 61:1203–1220. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Spagnuolo CM and Hegele RA: Recent
advances in treating hypertriglyceridemia in patients at high risk
of cardiovascular disease with apolipoprotein C-III inhibitors.
Expert Opin Pharmacother. 24:1013–1020. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Jorgensen AB, Frikke-Schmidt R,
Nordestgaard BG and Tybjaerg-Hansen A: Loss-of-function mutations
in APOC3 and risk of ischemic vascular disease. N Engl J Med.
371:32–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
TGHDL Working Group of the Exome
Sequencing Project, National Heart, Lung, and Blood Institute, .
Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA,
Lu Y, Tang ZZ, Zhang H, et al: Loss-of-function mutations in APOC3,
triglycerides, and coronary disease. N Engl J Med. 371:22–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Gill PK, Dron JS and Hegele RA: Genetics
of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol.
36:264–271. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Nurmohamed NS, Dallinga-Thie GM and Stroes
ESG: Targeting apoC-III and ANGPTL3 in the treatment of
hypertriglyceridemia. Expert Rev Cardiovasc Ther. 18:355–361. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Zheng C, Khoo C, Furtado J and Sacks FM:
Apolipoprotein C-III and the metabolic basis for
hypertriglyceridemia and the dense low-density lipoprotein
phenotype. Circulation. 121:1722–1734. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Hegele RA: APOC3 interference for familial
chylomicronaemia syndrome. touchREV Endocrinol. 18:82–83. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Schmitz J and Gouni-Berthold I: APOC-III
antisense oligonucleotides: A new option for the treatment of
hypertriglyceridemia. Curr Med Chem. 25:1567–1576. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Giammanco A, Spina R, Cefalù AB and Averna
M: APOC-III: A gatekeeper in controlling triglyceride metabolism.
Curr Atheroscler Rep. 25:67–76. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Witztum JL, Gaudet D, Freedman SD,
Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS,
Arca M, et al: Volanesorsen and triglyceride levels in familial
chylomicronemia syndrome. N Engl J Med. 381:531–542. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Gouni-Berthold I, Alexander VJ, Yang Q,
Hurh E, Steinhagen-Thiessen E, Moriarty PM, Hughes SG, Gaudet D,
Hegele RA, O'Dea LSL, et al: Efficacy and safety of volanesorsen in
patients with multifactorial chylomicronaemia (COMPASS): A
multicentre, double-blind, randomised, placebo-controlled, phase 3
trial. Lancet Diabetes Endocrinol. 9:264–275. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Witztum JL, Gaudet D, Arca M, Jones A,
Soran H, Gouni-Berthold I, Stroes ESG, Alexander VJ, Jones R, Watts
L, et al: Volanesorsen and triglyceride levels in familial
chylomicronemia syndrome: Long-term efficacy and safety data from
patients in an open-label extension trial. J Clin Lipidol.
17:342–355. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Tardif JC, Karwatowska-Prokopczuk E, Amour
ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E,
Bartlett VJ, Kingsbury J, et al: Apolipoprotein C-III reduction in
subjects with moderate hypertriglyceridaemia and at high
cardiovascular risk. Eur Heart J. 43:1401–1412. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Bergmark BA, Marston NA, Prohaska TA,
Alexander VJ, Zimerman A, Moura FA, Murphy SA, Goodrich EL, Zhang
S, Gaudet D, et al: Olezarsen for Hypertriglyceridemia in patients
at high cardiovascular risk. N Engl J Med. 390:1770–1780. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Gaudet D, Clifton P, Sullivan D, Baker J,
Schwabe C, Thackwray S, Scott R, Hamilton J, Given B, Melquist S,
et al: RNA interference therapy targeting apolipoprotein C-III in
hypertriglyceridemia. NEJM Evid. 2:EVIDoa22003252023. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Gaudet D, Pall D, Watts GF, Nicholls SJ,
Rosenson RS, Modesto K, San Martin J, Hellawell J and Ballantyne
CM: Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: The
SHASTA-2 randomized clinical trial. JAMA Cardiol. 9:620–630. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Ballantyne CM, Vasas S, Azizad M, Clifton
P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ,
et al: Plozasiran, an RNA interference agent targeting APOC3, for
mixed hyperlipidemia. N Engl J Med. 391:899–912. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Li JJ, Ma CS, Zhao D, Yan XW, Beijing
Heart S and Expert C: Lipoprotein(a) and cardiovascular disease in
Chinese population: A beijing heart society expert scientific
statement. JACC Asia. 2:653–665. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
van der Valk FM, Bekkering S, Kroon J,
Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ,
Verberne HJ, Scipione C, et al: Oxidized phospholipids on
Lipoprotein(a) elicit arterial wall inflammation and an
inflammatory monocyte response in humans. Circulation. 134:611–624.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Plakogiannis R, Sorbera M, Fischetti B and
Chen M: The role of antisense therapies targeting Lipoprotein(a). J
Cardiovasc Pharmacol. 78:e5–e11. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Tsimikas S, Karwatowska-Prokopczuk E,
Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E,
Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, et al:
Lipoprotein(a) reduction in persons with cardiovascular disease. N
Engl J Med. 382:244–255. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Stiekema LCA, Prange KHM, Hoogeveen RM,
Verweij SL, Kroon J, Schnitzler JG, Dzobo KE, Cupido AJ, Tsimikas
S, Stroes ESG, et al: Potent lipoprotein(a) lowering following
apolipoprotein(a) antisense treatment reduces the pro-inflammatory
activation of circulating monocytes in patients with elevated
lipoprotein(a). Eur Heart J. 41:2262–2271. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
O'Donoghue ML, JA GL, Knusel B, Gencer B,
Wang H, Wu Y, Kassahun H and Sabatine MS: Study design and
rationale for the Olpasiran trials of cardiovascular events And
lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am
Heart J. 251:61–69. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
O'Donoghue ML, Rosenson RS, Gencer B,
López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder
JF, et al: Small interfering RNA to reduce Lipoprotein(a) in
cardiovascular disease. N Engl J Med. 387:1855–1864. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Nissen SE, Wang Q, Nicholls SJ, Navar AM,
Ray KK, Schwartz GG, Szarek M, Stroes ESG, Troquay R, Dorresteijn
JAN, et al: Zerlasiran-A small-interfering RNA targeting
Lipoprotein(a): A phase 2 randomized clinical trial. JAMA.
332:1992–2002. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Diaz N, Perez C, Escribano AM, Sanz G,
Priego J, Lafuente C, Barberis M, Calle L, Espinosa JF, Priest BT,
et al: Discovery of potent small-molecule inhibitors of
lipoprotein(a) formation. Nature. 629:945–950. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Becker L, Cook PM and Koschinsky ML:
Identification of sequences in apolipoprotein(a) that maintain its
closed conformation: A novel role for apo(a) isoform size in
determining the efficiency of covalent Lp(a) formation.
Biochemistry. 43:9978–9988. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Becker L, Cook PM, Wright TG and
Koschinsky ML: Quantitative evaluation of the contribution of weak
lysine-binding sites present within apolipoprotein(a) kringle IV
types 6–8 to lipoprotein(a) assembly. J Biol Chem. 279:2679–2688.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Brunner C, Kraft HG, Utermann G and Muller
HJ: Cys4057 of apolipoprotein(a) is essential for lipoprotein(a)
assembly. Proc Natl Acad Sci USA. 90:11643–11647. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Guevara J Jr, Spurlino J, Jan AY, Yang CY,
Tulinsky A, Prasad BV, Gaubatz JW and Morrisett JD: Proposed
mechanisms for binding of apo[a] kringle type 9 to apo B-100 in
human lipoprotein[a]. Biophys J. 64:686–700. 1993. View Article : Google Scholar : PubMed/NCBI
|
